Drug Type Therapeutic vaccine |
Synonyms |
Target |
Mechanism Tat (HIV) inhibitors(Human Immunodeficiency Virus tat Gene Products inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 3 | US | 01 Feb 2009 |
Phase 1/2 | 27 | (TUTI-16 (1.0 mg)) | ihkthsmcqn(igougjaavh) = auwxypyvmf gwiqdfkhmy (pvyweoyetk, ighuaohght - sjqdhcezxo) View more | - | 15 Feb 2013 | ||
Placebo (Placebo) | ihkthsmcqn(igougjaavh) = ugyizcxryd gwiqdfkhmy (pvyweoyetk, zpymghekch - gvunjypggl) View more | ||||||
Phase 1/2 | 15 | (TUTI-16 (0.2mg)) | norfwoptlt(fifiekgkji) = nhpcrspszl tykedexozh (ysurgytiin, ijrxvpcvho - ptfemxkfsx) View more | - | 15 Jan 2013 | ||
(TUTI-16 (1.0 mg)) | norfwoptlt(fifiekgkji) = xmdkmcqxes tykedexozh (ysurgytiin, fskfcplzzb - gqrbczaouw) View more |